As of 2025-10-14, the EV/EBITDA ratio of C4 Therapeutics Inc (CCCC) is -0.59. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CCCC's latest enterprise value is 72.01 mil USD. CCCC's TTM EBITDA according to its financial statements is -121.62 mil USD. Dividing these 2 quantities gives us the above CCCC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.4x - 18.1x | 16.4x |
| Forward P/E multiples | 26.7x - 43.0x | 36.7x |
| Fair Price | (44.60) - (29.90) | (44.27) |
| Upside | -2213.7% - -1517.2% | -2198.3% |
| Date | EV/EBITDA |
| 2025-10-10 | -0.67 |
| 2025-10-09 | -0.77 |
| 2025-10-08 | -0.66 |
| 2025-10-07 | -0.68 |
| 2025-10-06 | -0.69 |
| 2025-10-03 | -0.69 |
| 2025-10-02 | -0.65 |
| 2025-10-01 | -0.62 |
| 2025-09-30 | -0.66 |
| 2025-09-29 | -0.66 |
| 2025-09-26 | -0.66 |
| 2025-09-25 | -0.64 |
| 2025-09-24 | -0.77 |
| 2025-09-23 | -0.87 |
| 2025-09-22 | -0.88 |
| 2025-09-19 | -1.21 |
| 2025-09-18 | -1.30 |
| 2025-09-17 | -1.34 |
| 2025-09-16 | -1.35 |
| 2025-09-15 | -1.45 |
| 2025-09-12 | -0.91 |
| 2025-09-11 | -0.95 |
| 2025-09-10 | -0.90 |
| 2025-09-09 | -0.93 |
| 2025-09-08 | -0.94 |
| 2025-09-05 | -0.95 |
| 2025-09-04 | -0.92 |
| 2025-09-03 | -0.86 |
| 2025-09-02 | -0.83 |
| 2025-08-29 | -0.88 |
| 2025-08-28 | -0.85 |
| 2025-08-27 | -0.87 |
| 2025-08-26 | -0.86 |
| 2025-08-25 | -0.84 |
| 2025-08-22 | -0.88 |
| 2025-08-21 | -0.88 |
| 2025-08-20 | -0.88 |
| 2025-08-19 | -0.97 |
| 2025-08-18 | -1.03 |
| 2025-08-15 | -0.80 |
| 2025-08-14 | -0.73 |
| 2025-08-13 | -0.72 |
| 2025-08-12 | -0.67 |
| 2025-08-11 | -0.77 |
| 2025-08-08 | -0.82 |
| 2025-08-07 | -0.87 |
| 2025-08-06 | -0.50 |
| 2025-08-05 | -0.53 |
| 2025-08-04 | -0.59 |
| 2025-08-01 | -0.60 |